Strategise to survive: PwC analyst
16 January, 2003 by Iain ScottAs the new year begins, market analysts are sounding the same warnings that they did in 2002 -- that Australian biotechnology companies must consider strategies like mergers and acquisitions and alliances to survive.
US Medarex casts around for local partners
15 January, 2003 by Melissa TrudingerUS monoclonal antibody company Medarex has been in Melbourne this week testing the waters for potential collaborations and partnerships.
Aussie biotech holding its own: Intersuisse
14 January, 2003 by Melissa TrudingerThe Australian biotechnology sector held its own through last year's tough market conditions, despite many companies recording a big drop in share price, according to a new report by stockbroking firm Intersuisse.
Recruiters predict a bumpy year ahead for biotech
13 January, 2003 by Pete YoungA conflicting pattern of cross-currents is swirling through the 2003 life sciences jobs pool, according to a survey of recruiting firms specialising in medical and scientific positions.
US billionaire offers $25m to Melbourne institutes
09 January, 2003 by Melissa TrudingerUS billionaire and fairy godfather Charles Feeney has offered Melbourne's Royal Children's Hospital and the Murdoch Children's Research Institute $AUD25 million to build new laboratories and clinical research facilities.
Happy holidays from all of us
20 December, 2002 by Iain ScottAustralian Biotechnology News will be closed for the holidays, until January 6, 2003.
Bioprospect signs deal with US company Diversa
20 December, 2002 by Pete YoungListed company BioProspect has signed a pact with a second major drug developer interested in testing its library of compounds extracted from Australian plants.
Taxing moves in bioindustry
19 December, 2002 by Pete YoungAustralian bioindustry has a sweeping wish list of tax reform measures it desperately wants to see implemented. The trouble is, forcing through significant changes to the national tax structure has the same torturously long gestation period as developing a major new drug.
Bioscientists appointed to innovation board
12 December, 2002 by Melissa TrudingerSeveral prominent bioscientists, including Prof Adrienne Clarke, Prof Peter Doherty, Cerylid's Jackie Fairley and Prof Alan Trounson, have been appointed to the Victorian government's new Innovation Economy Advisory Board, set up to drive innovation across the state's economy.
Commercialisation: Doing the hard-sell on research
10 December, 2002 by David BinningMuch to the chagrin of those actually at the coalface, the technical achievements of our leading scientific institutions and successful partnering with industry to bring them to market have long been tainted by the myth that not enough is being done and other countries are doing it better.
NSW govt launches BioLink business alliance
10 December, 2002 by Iain ScottThe NSW government has pledged $2.6 million over the next four years towards the establishment of a new business alliance created by the Garvan Institute of Medical Research, the Westmead research hub and the Hunter Medical Research Institute.
National priorities allow room for biotech
09 December, 2002 by Graeme O'NeillBetween the broad brushstrokes of the Federal government's four National Research Priorities, announced last Friday by Prime Minister John Howard, there is room for a major contribution from Australia's biotechnology and biomedical researchers.
European research program thrown open to Aussies
04 December, 2002 by Melissa TrudingerAustralian researchers have the opportunity to participate in the Sixth Framework Program for European Research and Technological Development (FP6), but they should think hard about the value they can bring to collaborative projects and be prepared to come with their own funding, according to presenters at a special symposium held by the Australasian Research Management Society at the Australian Health and Medical Research Congress (AHMRC) last week.
PanVax collaborates with the Institute Pasteur
02 December, 2002 by Melissa TrudingerPrima BioMed subsidiary PanVax has entered into a research collaboration with the Institute Pasteur in France.
Khan resumes Biota board campaign
02 December, 2002 by Pete YoungThe majority shareholder in Biota Holdings, Perth lawyer Farooq Khan, has resumed his campaign to force his way onto the listed biotech's board.
